---
title: "Biotechnology concept stocks rose after hours, reports indicate that the U.S. FDA vaccine director will resign"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278179446.md"
description: "Replimune Group Inc. (REPL) rose 12% in after-hours trading, Capricor Therapeutics Inc. (CAPR) rose 7.5%. UniQure N.V. rose 35%, Sarepta Therapeutics rose 6.2%"
datetime: "2026-03-06T23:12:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278179446.md)
  - [en](https://longbridge.com/en/news/278179446.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278179446.md)
---

# Biotechnology concept stocks rose after hours, reports indicate that the U.S. FDA vaccine director will resign

Replimune Group Inc. (REPL) rose 12% in after-hours trading, Capricor Therapeutics Inc. (CAPR) rose 7.5%.

UniQure N.V. rose 35%, Sarepta Therapeutics rose 6.2%

### Related Stocks

- [QURE.US](https://longbridge.com/en/quote/QURE.US.md)
- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)
- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)

## Related News & Research

- [11:34 ETQURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026](https://longbridge.com/en/news/282366271.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment]]>](https://longbridge.com/en/news/282578794.md)
- [FDA issues complete response letter to Replimune’s RP1 for melanoma](https://longbridge.com/en/news/282511585.md)
- [<![CDATA[FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment ]]>](https://longbridge.com/en/news/282567251.md)